Merck’s V116 Pneumococcal Vaccine Shows Promising Data Against Pfizer’s Prevnar 20
Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled new data from a late-stage trial...
Merck
Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda
Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...
MSD to Acquire Caraway Therapeutics for USD 610 Million to Boost Neurodegenerative Disease Portfolio
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced an agreement to purchase Caraway Therapeutics,...
Merck KGaA Completes Second Phase of Biologics Testing Center Expansion in China
Germany’s major life science company, Merck KGaA (ETR: MRK), has announced the completion of the...
Aurobindo Pharma’s China Plant Secures EU GMP Approval, Eyes Revenue Generation
India-based Aurobindo Pharma reportedly received EU GMP approval for its China-based manufacturing plant last week,...
Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches
Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this...
Merck Reports Q3 2023 Financial Results with Mixed Performance Across Segments
Germany-based Merck (ETR: MRK) has released its financial results for the third quarter of 2023,...
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...
Seagen’s Adcetris Combo with Keytruda Shows Promising Results in Phase II Study
Seagen (NASDAQ: SGEN), currently in the process of being acquired by Pfizer (NYSE: PFE), has...
Merck Reports 9% Global Sales Growth in Q3 2023, Boosted by Keytruda and Gardasil
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has reported a robust 9%...
MSD Halts Phase II Trials for Glutamate Modulator MK-1942 in Alzheimer’s and Depression
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of two Phase II...
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
Merck KGaA Partners with Porton Pharma for Next-Gen ADC Platform Development
German pharmaceutical giant Merck KGaA (ETR: MRK) has entered into a strategic partnership with China-based...
MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy
Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership...
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
AstraZeneca Alum Yu Yuping Appointed Vice-President at Merck KGaA’s China Unit
Yu Yuping, a seasoned professional with a distinguished career at AstraZeneca (AZ, NASDAQ: AZN), has...
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...
FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension
The US Food and Drug Administration (FDA) has granted priority review status to an indication...
EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...